دورية أكاديمية

Prescribing paradigm shift?:Applying the 2019 European Society of Cardiology-led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland

التفاصيل البيبلوغرافية
العنوان: Prescribing paradigm shift?:Applying the 2019 European Society of Cardiology-led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland
المصدر: Scottish Diabetes Research Network Epidemiology Group 2020 , ' Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland ' , Diabetes Care , vol. 43 , no. 9 , pp. 2034-2041 . https://doi.org/10.2337/dc20-0120Test
سنة النشر: 2020
المجموعة: Discovery - University of Dundee Online Publications
مصطلحات موضوعية: Aged, Cardiology/organization & administration, Cross-Sectional Studies, Diabetes Mellitus, Type 2/drug therapy, Female, Glucagon-Like Peptide-1 Receptor/agonists, Glycated Hemoglobin A/analysis, Guideline Adherence/statistics & numerical data, History, Humans, Hypoglycemic Agents/therapeutic use, Male, Middle Aged, Patient Selection, Practice Guidelines as Topic/standards, Practice Patterns, Physicians'/history, Registries, Retrospective Studies, Risk Assessment, Risk Factors, Scotland/epidemiology, Societies, Medical/standards, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
الوقت: 21st Century
الوصف: OBJECTIVE In 2019, the European Society of Cardiology led and released new guidelines for diabetes cardiovascular risk management, reflecting recent evidence of cardiovascular disease (CVD) reduction with sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and some glucagon-like peptide 1 receptor agonists (GLP-1RAs) in type 2 diabetes (T2D). A key recommendation is that all those with T2D who are (antihyperglycemic) drug naïve or on metformin monotherapy should be CVD risk stratified and an SGLT-2i or a GLP-1RA initiated in all those at high or very high risk, irrespective of glycated hemoglobin. We assessed the impact of these guidelines in Scotland were they introduced as is. RESEARCH DESIGN AND METHODS Using a nationwide diabetes register in Scotland, we did a cross-sectional analysis, using variables in our register for risk stratification at 1 January 2019. We were conservative in our definitions, assuming the absence of a risk factor where data were not available. The risk classifications were applied to people who were drug naïve or on metformin monotherapy and the anticipated prescribing change calculated. RESULTS Of the 265,774 people with T2D in Scotland, 53,194 (20.0% of those with T2D) were drug naïve, and 56,906 (21.4%) were on metformin monotherapy. Of these, 74.5% and 72.4%, respectively, were estimated as at least high risk given the guideline risk definitions. CONCLUSIONS Thus, 80,830 (30.4%) of all those with T2D ( n = 265,774) would start one of these drug classes according to table 7 and figure 3 of the guideline. The sizeable impact on drug budgets, enhanced clinical monitoring, and the trade-off with reduced CVD-related health care costs will need careful consideration.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: https://discovery.dundee.ac.uk/en/publications/11798f26-74ba-42c0-97dc-5cc97e1dded2Test
DOI: 10.2337/dc20-0120
الإتاحة: https://doi.org/10.2337/dc20-0120Test
https://discovery.dundee.ac.uk/en/publications/11798f26-74ba-42c0-97dc-5cc97e1dded2Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.B83410D2
قاعدة البيانات: BASE